1202O - Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the...

Date 10 October 2016
Event ESMO 2016 Congress
Session NSCLC, metastatic 2
Topics Non-Small-Cell Lung Cancer, Metastatic
Presenter Charlotte Leduc
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors C. Leduc1, H. Blons2, B. Besse3, J. Merlio4, D. Debieuvre5, A. Lemoine6, I. Monnet7, D. Pouessel8, P.P. Bringuier9, M. Poudenx10, I. Rouquette11, F. Vaylet12, F. Morin13, A. Langlais13, E. Quoix1, G. Zalcman14, D. Moro-Sibilot15, J. Cadranel16, M. Beau-Faller1, F. Barlesi17
  • 1Pneumologie, C.H.U. Strasbourg-Nouvel Hopital Civil, 67000 - Strasbourg/FR
  • 2Department Of Biology, Hopital European George Pompidou, Paris/FR
  • 3Departement Of Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4Biologie Des Tumeurs, CHU Hôpital Haut-Lévêque, Bordeaux/FR
  • 5Pneumologie, Hopital Emile Muller, 68070 - Mulhouse/FR
  • 6Oncogenetics And Biochemistry, Hopital Paul Brousse, 94800 - Villejuif/FR
  • 7Pneumologie, CHI de Créteil,, 94010 - Créteil/FR
  • 8Medical Oncology, Hôpital St. Louis, 75010 - Paris/FR
  • 9Laboratoire Central D'anatomie Et De Cytologie Pathologiques, Groupement Hospitalier Edouard Herriot, 69003 - Lyon/FR
  • 10Medical Oncology Departement, Centre Antoine Lacassagne, 06100 - Nice/FR
  • 11Pathology, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse/FR
  • 12Pneumologie, Hôpital Militaire Percy, Clamart/FR
  • 13Clinical Research Unit, IFCT (Intergroupe Francophone de Cancérologie Thoracique)., 75009 - PARIS/FR
  • 14Pneumologie, Hopital Bichat Claude Bernard, Paris/FR
  • 15Thoracic Oncology, CHU Grenoble - Hopital Michallon, 38043 - La Tronche/FR
  • 16Pneumology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 17Multidisciplinary Oncology And Therapeutic Innovations Department, Aix-Marseille University - Faculté de Médecine Nord, Marseille/FR



EGFR mutations are associated with variable response to EGFR-TKI depending on the types of exons, mutations or clinical characteristics. To better understand these features we reviewed all cases of EGFR mutated NSCLC collected in the Biomarkers France database (Barlesi et al, Lancet 2016).


Among the 17,664 patients, 1837 (10.3%) with an EGFR mutated NSCLC were analyzed for their biological and clinical characteristics.


EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.6%), 931 (50.6%), 102 (5.6%) and 702 (38.2%) patients among which 70 had never been described. Proportion of smokers was higher in exon 18 (20%) and exon 20 (19%) compared to exon 19 (11%) and 21 (11%) (p = 0.002). Personal history of cancer was related in 226 patients (19.2%), irrespective of the exons. T790M mutated patients (n = 42) were excluded for survival analysis. Median follow-up was 36.7 [36.4-37] months. Median overall survivals (OS), first-line progression-free survivals (PFS) and disease control rates (DCR) under first-line EGFR-TKI according to the type of EGFR mutation are summarized in table 1. Median OS was longer for exon 19 deletions compared to L858R mutations (26.5 vs. 21.3 months, p = 0.045). In exon 19, there was no difference in OS based on the length of the deletion. In exon 21, median OS was longer for L858R than for L861Q or other substitutions or wild-type (22.4 vs. 14.1 vs. 14.9 vs. 11.8, p = 


Common and non-common EGFR mutations presented different clinical characteristics. Among common mutations, exon 19 mutated patients had better outcomes.

Clinical trial identification


Legal entity responsible for the study



INCa, AstraZeneca


C. Leduc: Chugai. M. Beau-Faller: AstraZeneca, Boerhinger-Ingelheim, Roche. All other authors have declared no conflicts of interest.